GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
JJ Meier - Nature Reviews Endocrinology, 2012 - nature.com
… to native GLP-1 and activate the GLP-1 receptor. However, in contrast with native GLP-1, …
individual characteristics and major differences between the various GLP-1 receptor agonists …
individual characteristics and major differences between the various GLP-1 receptor agonists …
Defining the role of GLP-1 receptor agonists for individualized treatment of type 2 diabetes
D Yabe, Y Seino - Expert Review of Endocrinology & Metabolism, 2014 - Taylor & Francis
… receptor agonists (GLP-1 RAs) over the past decade, incretin therapy has become established
as an important treatment … This review focuses on the use of GLP-1 RAs in the treatment of …
as an important treatment … This review focuses on the use of GLP-1 RAs in the treatment of …
Biased β-agonists favoring Gs over β-arrestin for individualized treatment of obstructive lung disease
… For example, the μ-opioid receptor agonist oliceridine does not … An agonist acting at the
angiotensin II type 1 receptor has … the balanced agonist acting at this receptor. For the 5-HT 1A …
angiotensin II type 1 receptor has … the balanced agonist acting at this receptor. For the 5-HT 1A …
Advances in dopamine receptor agonists for the treatment of Parkinson's disease
F Stocchi, M Torti, C Fossati - Expert opinion on pharmacotherapy, 2016 - Taylor & Francis
… : Dopamine agonists (DA) are a class of agents which directly stimulate dopamine receptors
… of recent literature evidences, would help clinician in the management of treatment with DA. …
… of recent literature evidences, would help clinician in the management of treatment with DA. …
Markers of muscarinic deficit for individualized treatment in schizophrenia
H Stuke - Frontiers in Psychiatry, 2023 - frontiersin.org
… The current success of agonists at muscarinic acetylcholine receptors in the treatment of …
In this case, it would be important for individualized treatment to find specific predictors of …
In this case, it would be important for individualized treatment to find specific predictors of …
[HTML][HTML] Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson's Disease
JS Liu, Y Chen, DD Shi, BR Zhang… - Current …, 2023 - ncbi.nlm.nih.gov
… used dopamine receptor agonists include pramipexole, … receptor agonists and genomics
mainly focus on the effect of gene polymorphism on the efficacy of dopamine receptor agonists. …
mainly focus on the effect of gene polymorphism on the efficacy of dopamine receptor agonists. …
… -hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual …
LHRH-agonists in Early Breast Cancer Overview group - The Lancet, 2007 - Elsevier
… randomised comparison between a systemic treatment and an LHRH agonist. In some trials…
the treatments were with an LHRH agonist. The randomised addition of an LHRH agonist …
the treatments were with an LHRH agonist. The randomised addition of an LHRH agonist …
[HTML][HTML] Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome
T Polster - Epilepsy & Behavior, 2019 - Elsevier
… fenfluramine as a treatment for seizures in Dravet syndrome. This concept was successfully
evaluated in a zebrafish model and led to a Phase 3 trial of fenfluramine to treat seizures in …
evaluated in a zebrafish model and led to a Phase 3 trial of fenfluramine to treat seizures in …
[HTML][HTML] Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts
R Weiskirchen, S Weiskirchen, F Tacke - F1000Research, 2018 - ncbi.nlm.nih.gov
… In the following, we will briefly sum up the current treatment regimens and the pathogenic
basis of anti-fibrotic properties of specific treatments in hepatic fibrosis based on either …
basis of anti-fibrotic properties of specific treatments in hepatic fibrosis based on either …
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
RG Pertwee - British journal of pharmacology, 2009 - Wiley Online Library
… level or coupling efficiency in particular tissues as a biomarker for selecting patient
subpopulations that would benefit most from treatment with a CB 1 /CB 2 receptor partial agonist. …
subpopulations that would benefit most from treatment with a CB 1 /CB 2 receptor partial agonist. …
相关搜索
- glp 1 receptor agonists
- peptide 1 receptor agonists
- dopamine receptor agonists
- cannabinoid receptor agonists
- obstructive lung disease individualized treatment
- seizures in dravet syndrome individualized treatment
- receptor agonists diabetes mellitus
- receptor agonists dpp 4 inhibitors
- receptor agonists type 2 diabetes
- receptor agonists treatment of patients
- individualized treatment of type 2 diabetes
- β arrestin individualized treatment
- receptor agonists comparison review
- receptor agonists practical guidance
- receptor agonists user's guide
- receptor agonists clinical review